How Alendronate (Fosamax) Affects Alkaline Phosphatase Levels

What Alkaline Phosphatase Measures and Why It Matters in Bone Health

Alkaline phosphatase is a group of isoenzymes found in bone, liver, kidney, and intestine. In the context of osteoporosis, the bone-specific isoform (BSAP) reflects osteoblast activity and the rate of new bone formation. Total serum ALP captures both hepatic and skeletal sources, which is why distinguishing between the two matters when interpreting results during bisphosphonate therapy 1.

When bone turnover is high, as in untreated postmenopausal osteoporosis or Paget disease, ALP rises because osteoblasts are working overtime to fill resorption pits created by overactive osteoclasts. The enzyme acts as a biochemical mirror of skeletal remodeling. A 2006 meta-analysis of bone turnover markers in the Journal of Bone and Mineral Research confirmed that baseline ALP independently predicted fracture risk in postmenopausal women, with those in the highest quartile facing roughly double the hip fracture risk compared to the lowest quartile 2.

This relationship between ALP and fracture risk makes it a practical, inexpensive tool for tracking treatment response. Unlike dual-energy X-ray absorptiometry (DXA), which detects bone density changes over 1 to 2 years, ALP shifts become measurable within weeks to months of starting therapy.

How Alendronate Lowers Alkaline Phosphatase: The Pharmacologic Mechanism

Alendronate binds to hydroxyapatite on bone surfaces and is internalized by osteoclasts during resorption. Once inside the cell, it inhibits farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, disrupting the prenylation of small GTPases essential for osteoclast survival 3. The osteoclast loses its ruffled border, detaches, and undergoes apoptosis.

This suppression of osteoclast function triggers a coupled decline in osteoblast activity. Bone remodeling operates as a paired sequence: resorption precedes formation. When resorption drops, the demand signal driving new osteoblast recruitment weakens. Fewer active osteoblasts means less ALP released into the bloodstream 4.

The effect is dose-dependent. In the Phase III Fracture Intervention Trial (FIT), participants receiving alendronate 10 mg daily showed a mean reduction in bone-specific ALP of approximately 25 to 30 percent from baseline by 6 months, a decline that persisted through the 3-year study period 5. Total ALP fell by a similar proportion, though individual variation was wider because hepatic ALP contributed a variable fraction of the total. The skeletal-specific fraction captured the drug's true pharmacodynamic footprint more precisely.

One point often missed: alendronate does not directly inhibit ALP enzyme activity. The reduction is indirect, driven entirely by fewer osteoblasts being recruited to remodeling sites. This distinction matters clinically because a rising ALP on alendronate therapy should not be attributed to "drug resistance" affecting enzyme function. It should trigger evaluation for non-compliance, a new metabolic bone condition, or hepatobiliary disease.

Expected Timeline: When ALP Changes Become Measurable

The timeline follows a predictable arc. ALP begins declining within 4 to 6 weeks of starting alendronate 70 mg weekly. By 3 months, most patients show a 15 to 20 percent reduction from their pretreatment value 6. The nadir arrives between 6 and 12 months. After that, levels plateau and remain suppressed for as long as the patient continues therapy.

The FIT extension data (FLEX trial) demonstrated that women who took alendronate for 10 years maintained bone-specific ALP suppression of roughly 30 percent below their original baseline throughout the entire treatment period 7. Those who discontinued alendronate after 5 years and switched to placebo experienced a gradual rise in ALP over the following 5 years, though levels did not fully return to pretreatment values. This residual suppression reflects alendronate's long skeletal half-life (estimated at over 10 years) as drug slowly releases from bone matrix.

Speed of response varies by individual. Patients with higher baseline bone turnover, such as women within the first 5 years of menopause, tend to show larger absolute reductions. Those with already-low turnover at baseline may see modest numerical changes that still represent proportionally meaningful suppression 8.

Bone-Specific ALP vs. Total ALP: Which Test to Order

Total serum ALP is included in every standard comprehensive metabolic panel. It costs little and requires no special handling. The problem is specificity. In a patient with coexisting fatty liver disease or biliary stasis, total ALP may remain elevated despite adequate skeletal suppression. Total ALP can mislead.

Bone-specific ALP (BSAP) isolates the skeletal isoform using immunoassay or heat-inactivation methods. The 2020 International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry (IFCC) joint position paper recommended BSAP and procollagen type I N-propeptide (P1NP) as the reference bone formation markers for clinical use 9. Dr. Richard Eastell, co-author of the IOF-IFCC guidelines and professor of bone metabolism at the University of Sheffield, stated: "Bone-specific alkaline phosphatase and P1NP provide the most reliable window into osteoblast activity during anti-resorptive treatment, and clinicians should request these rather than relying solely on total ALP when discordant results arise" 9.

For most patients on alendronate, total ALP is sufficient for routine monitoring. Reserve BSAP testing for situations where total ALP is discordant with clinical expectations: a patient whose total ALP is rising despite good adherence, or a patient with known liver disease where the hepatic fraction confounds interpretation.

Clinical Trial Evidence: The FIT Trial and Beyond

The Fracture Intervention Trial remains the landmark dataset. Published in JAMA in 1998, FIT enrolled 6,459 postmenopausal women with low femoral neck bone density. The vertebral fracture arm (FIT-1, N=2,027) studied women with existing vertebral fractures, while FIT-2 (N=4,432) enrolled women without prevalent fractures 5.

Results were clear. Over 3 years, alendronate 10 mg daily reduced hip fractures by 44 percent (relative risk 0.56, 95% CI 0.32-0.97) and clinical vertebral fractures by 55 percent in FIT-1 5. Bone turnover markers, including ALP, declined within the first 6 months and remained suppressed. The magnitude of early ALP suppression correlated with fracture risk reduction: women in the lowest tertile of on-treatment ALP had the fewest incident fractures 10.

A post hoc analysis of the FIT data showed that a 30 percent or greater reduction in BSAP at 12 months was associated with a 40 percent lower risk of non-vertebral fractures compared to women with less than 30 percent reduction 10. This finding established ALP suppression as a surrogate marker for treatment efficacy, though it has not replaced DXA as the primary monitoring tool.

The FOSIT trial (Fosamax International Trial, N=1,908) independently confirmed these biochemical findings across 34 countries. BSAP fell by a mean of 29.2 percent from baseline at 12 months in the alendronate 10 mg group versus a 4.5 percent decline in the placebo group (P<0.001) 11.

Monitoring ALP During Alendronate Therapy: A Practical Schedule

The American Association of Clinical Endocrinologists (AACE) 2020 clinical practice guidelines for postmenopausal osteoporosis recommend measuring a bone turnover marker, such as ALP or CTX, at baseline and at 3 to 6 months after starting therapy to confirm biochemical response 12. Dr. Pauline Camacho, lead author of the AACE guideline and director of the Loyola University Osteoporosis Center, wrote: "A decline in bone turnover markers of at least 25 percent from baseline provides early reassurance that the patient is absorbing the medication and that osteoclast suppression is occurring as expected" 12.

A practical monitoring schedule for most patients:

Baseline: Draw total ALP (or BSAP if available) before or within the first week of starting alendronate. Record this value in the chart as the reference point.

3 to 6 months: Repeat ALP. A decline of 25 percent or more from baseline confirms adequate pharmacodynamic response. If the decline is less than 15 percent, assess adherence first. Alendronate must be taken on an empty stomach with plain water, 30 minutes before any food, drink, or other medication. Even small deviations reduce absorption dramatically: bioavailability is only 0.6 to 0.7 percent under ideal conditions 13.

12 months: Consider a repeat measurement to confirm the plateau. This time point aligns with the first annual DXA follow-up in some practice patterns.

Annually thereafter: ALP can be checked alongside routine metabolic panels. Stability confirms ongoing suppression. A rise of more than 25 percent above the on-treatment nadir should prompt investigation: medication adherence, new hepatic pathology, vitamin D deficiency, or secondary causes of bone loss such as hyperparathyroidism.

When ALP Does Not Drop: Troubleshooting Persistent Elevation

ALP failing to decline after 6 months of alendronate therapy narrows the differential. The most common cause is poor adherence or incorrect dosing technique, accounting for the majority of apparent non-response in clinical practice 14.

Ask three questions. Is the patient taking the tablet with 8 ounces of plain water only? Is she waiting a full 30 minutes before eating or drinking anything else? Is she remaining upright during that interval? Each step affects absorption. Coffee, juice, calcium supplements, and proton pump inhibitors taken concurrently all reduce alendronate bioavailability significantly 13.

If dosing technique is verified, consider:

Hepatic contribution. Order a GGT (gamma-glutamyl transferase). If GGT is elevated alongside ALP, the rise is likely hepatobiliary, not skeletal. BSAP can resolve the question definitively.

Vitamin D deficiency. Serum 25-hydroxyvitamin D below 20 ng/mL drives secondary hyperparathyroidism, which accelerates bone turnover and can offset bisphosphonate suppression. The Endocrine Society recommends maintaining 25(OH)D above 30 ng/mL during anti-resorptive therapy 15.

Secondary osteoporosis. Screen for hyperthyroidism, primary hyperparathyroidism, celiac disease, and multiple myeloma. Each can raise ALP independently.

Paget disease overlap. ALP in Paget disease is often markedly elevated, sometimes 3 to 10 times the upper limit of normal. Standard osteoporosis doses of alendronate (70 mg/week) may be insufficient. Paget-specific dosing is 40 mg daily for 6 months 16.

ALP After Stopping Alendronate: The Rebound Curve

When alendronate is discontinued, ALP does not snap back immediately. The FLEX trial showed that women who stopped alendronate after 5 years experienced a gradual rise in BSAP over the following 12 to 24 months, reaching levels approximately 15 to 20 percent above the on-treatment nadir but still below their original pretreatment baseline at 5 years post-discontinuation 7.

This slow rebound distinguishes alendronate from denosumab, where bone turnover markers can overshoot pretreatment levels within 6 months of stopping, creating a rebound resorption window associated with increased vertebral fracture risk 17. Alendronate's persistent skeletal binding prevents this rapid overshoot.

For patients entering a "bisphosphonate holiday" after 5 years of therapy (per the AACE recommendation for moderate-risk patients), ALP or CTX measurements every 6 to 12 months can signal when bone turnover has risen enough to warrant restarting treatment. A practical threshold: if ALP rises above 75 percent of the pretreatment baseline, consider resuming therapy or switching agents 12.

Comparing ALP Response Across Bisphosphonates and Other Anti-Resorptives

Alendronate is not unique in lowering ALP. All nitrogen-containing bisphosphonates suppress bone turnover markers through the same FPPS inhibition pathway. Zoledronic acid (Reclast), given as a 5 mg annual IV infusion, reduces BSAP by approximately 30 to 35 percent at 12 months, slightly greater than oral alendronate, likely due to 100 percent bioavailability via the intravenous route 18.

Risedronate (Actonel) produces ALP reductions of roughly 20 to 25 percent, modestly less than alendronate in head-to-head biochemical comparisons, though no trial has demonstrated a fracture-endpoint difference between the two oral agents based on the degree of ALP suppression 19.

Denosumab (Prolia) suppresses BSAP more profoundly than any bisphosphonate, with reductions of 50 to 60 percent at 6 months in the FREEDOM trial (N=7,868) 20. This deeper suppression reflects denosumab's mechanism: complete RANKL blockade eliminates virtually all osteoclast formation, whereas bisphosphonates primarily kill mature osteoclasts while allowing some ongoing recruitment.

Anabolic agents work in the opposite direction. Teriparatide (Forteo) and romosozumab (Evenity, during its bone-forming phase) raise ALP, sometimes substantially. Switching from teriparatide to alendronate typically produces a steep ALP decline over the first 3 to 6 months as the anabolic stimulus is replaced by anti-resorptive suppression 21.

Special Populations: Where ALP Interpretation Gets Complicated

Men on alendronate. The key trial of alendronate for male osteoporosis (N=241) showed BSAP reductions of 30 percent at 12 months, comparable to the female data 22. Interpretation is the same. One caveat: men over 65 with unexplained ALP elevation should be screened for prostate cancer, which can raise bone ALP through osteoblastic metastases.

Glucocorticoid-induced osteoporosis. Patients on chronic prednisone (7.5 mg/day or more) may have suppressed bone turnover at baseline from glucocorticoid effects on osteoblasts. Starting alendronate in this population may produce smaller absolute ALP reductions because the baseline is already low. The American College of Rheumatology recommends bisphosphonate prophylaxis for patients expected to receive glucocorticoids for 3 months or longer at prednisone-equivalent doses of 2.5 mg/day or more 23.

Chronic kidney disease. ALP in CKD stages 3b through 5 reflects both bone turnover and the hepatic effects of uremia. KDIGO 2017 guidelines suggest that persistently rising ALP in CKD may indicate high-turnover renal osteodystrophy, and bisphosphonate use in patients with eGFR <35 mL/min is generally avoided due to accumulation risk and the possibility of adynamic bone disease 24.

The Clinical Bottom Line: What Your ALP Result Means on Fosamax

A total ALP that drops 25 to 30 percent from baseline within 6 months of starting alendronate 70 mg weekly confirms the drug is being absorbed and is suppressing bone turnover as expected. Patients who achieve at least a 30 percent reduction in BSAP at 12 months had a 40 percent lower non-vertebral fracture risk in the FIT trial analysis 10. If ALP fails to decline, verify dosing technique and vitamin D status before considering the medication ineffective or switching agents.